ASCLF (Ascletis Pharma) Depreciation, Depletion and Amortization: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASCLF Ascletis Pharma Inc ASCLF
36 GF Score
Price $1.30
GF Value $0.02
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ascletis Pharma Depreciation, Depletion and Amortization?

Ascletis Pharma ASCLF 36 Depreciation, Depletion and Amortization is $0.00 Mil as of Dec. 2025. GuruFocus rates ASCLF with a GF Score™ of 36/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Ascletis Pharma's depreciation, depletion and amortization for the six months ended in Dec. 2025 was $0.00 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.


Ascletis Pharma  (OTCPK:ASCLF) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Ascletis Pharma Depreciation, Depletion and Amortization Related Terms


Ascletis Pharma Depreciation, Depletion and Amortization Historical Data

* Premium members only.

The historical data trend for Ascletis Pharma's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascletis Pharma Depreciation, Depletion and Amortization Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.64 4.33 2.59 2.81 2.50

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASCLF
36GF Score
Ascletis Pharma Inc ASCLF
Depreciation, Depletion and Amortization is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascletis Pharma Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Depreciation, Depletion and Amortization of $0.00 Mil mean?
Ascletis Pharma (ASCLF) has a Depreciation, Depletion and Amortization of $0.00 Mil as of Dec. 2025. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Ascletis Pharma.
Is Ascletis Pharma's Depreciation, Depletion and Amortization too high?
Ascletis Pharma's current Depreciation, Depletion and Amortization is $0.00 Mil. Overall, Ascletis Pharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Depreciation, Depletion and Amortization compare to VRTX and REGN?
Ascletis Pharma's Depreciation, Depletion and Amortization of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Depreciation, Depletion and Amortization for a Biotechnology company?
A good Depreciation, Depletion and Amortization depends on the Biotechnology industry context. However, Depreciation, Depletion and Amortization should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Depreciation, Depletion and Amortization mean?
A high Depreciation, Depletion and Amortization can signal that a stock is expensive relative to its fundamentals. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Ascletis Pharma. Ascletis Pharma's current Depreciation, Depletion and Amortization is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.30 — trading 6400% above its estimated fair value. The current Depreciation, Depletion and Amortization is $0.00 Mil. Ascletis Pharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Depreciation, Depletion and Amortization calculated?
Depreciation, Depletion and Amortization is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Depreciation, Depletion and Amortization is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascletis Pharma (ASCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of $1.30 is trading 6400% above its estimated GF Value™ of $0.02. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for ASCLF:

  • Depreciation, Depletion and Amortization: $0.00 Mil
  • GF Value™: $0.02 vs. price of $1.30 (6400% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascletis Pharma Business Description

Other Exchanges 01672:Hong Kong2VJ:Germany
Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
36GF Score

Get the complete analysis for ASCLF

Depreciation, Depletion and Amortization is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price
$0.02
GF Value